Rhythm Pharmaceuticals, Inc.
RYTM
NASDAQ·Healthcare·Biotechnology·Mkt cap $7.0B
$102.74
▼ -2.05%
P/E
-33.04
Mkt Cap
$7.0B
52-Wk Range
$74.50–$122.20
52-Week Range
$74.50 - $122.20
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 3.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- First-mover advantage with FDA-approved IMCIVREE for rare genetic obesity
- Specialized expertise in melanocortin-4 receptor pathway and monogenic obesity genetics
- Established clinical relationships and research collaborations including Bardet-Biedl syndrome registry
- Focused pipeline addressing underserved rare disease markets with limited competition
Bear Case
1 risk
- Above-average volatility (beta 2.0).
Growth
Strong growth ahead
IMCIVREE market expansion and patient identification in rare obesity indications
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Strong
+18.9% over 3m
Quality
Excellent
High-growth business (54% revenue growth, 89% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying RYTM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 4, 2026
Reported EPS of -$0.73 vs -$0.81 consensus (+9.6% surprise). Revenue of $71.3M vs $67.7M expected (+5.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+9.6%
Revenue trend · last 8Q
—
+73%
+26%
+67%
+54%
+37%
+84%
+47%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$33.3M
$41.8M
$32.7M
$48.5M
$51.3M
$57.3M
$60.1M
$71.3M
Margins · last 8Q
Gross
87.5%
Operating
-68.1%
Profit
-69.2%
Wall Street consensus
11 analysts · 91% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
91%
Hold
9%
Sell
0%
Median Price Target
—
Latest: Deutsche Bank · Aug 28, 2026
vs Industry
How RYTM stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related